
    
      This will be a Phase 2, multicenter, randomized, double-blinded, dose-ranging, parallel arm
      comparison study in male and non-pregnant female subjects, 9 through 45 years of age
      (inclusive) with facial acne vulgaris. This dose-ranging study, intended to identify the
      dose(s), will consist of 7 study visits over 14 weeks:
    
  